{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:31:05Z","timestamp":1792593065946,"version":"4.5.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003443","name":"Ministry of Education and Science of the Russian Federation","doi-asserted-by":"publisher","award":["075-15-2022-304"],"award-info":[{"award-number":["075-15-2022-304"]}],"id":[{"id":"10.13039\/501100003443","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.bbcan.2024.189151","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:29:05Z","timestamp":1720484945000},"page":"189151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Metabolomic biomarkers of multiple myeloma: A systematic review"],"prefix":"10.1016","volume":"1879","author":[{"given":"Valeria G.","family":"Varzieva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia V.","family":"Mesonzhnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina S.","family":"Ilgisonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri N.","family":"Belenkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria V.","family":"Kozhevnikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana A.","family":"Appolonova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bbcan.2024.189151_bb0005","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.soncn.2017.05.012","article-title":"Pathobiology and diagnosis of multiple myeloma","volume":"33","author":"Brigle","year":"2017","journal-title":"Semin. Oncol. Nurs."},{"issue":"3","key":"10.1016\/j.bbcan.2024.189151_bb0010","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","year":"2021","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189151_bb0015","first-page":"3","article-title":"Epidemiology, staging, and Management of Multiple Myeloma","volume":"9","author":"Padala","year":"2021","journal-title":"Med Sci (Basel)."},{"issue":"12","key":"10.1016\/j.bbcan.2024.189151_bb0020","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","year":"2014","journal-title":"Lancet Oncol."},{"issue":"15","key":"10.1016\/j.bbcan.2024.189151_bb0025","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.bbcan.2024.189151_bb0030","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.ejca.2005.11.037","article-title":"The role of anatomic and functional staging in myeloma: description of Durie\/Salmon plus staging system","volume":"42","year":"2006","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.bbcan.2024.189151_bb0035","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of Haematolymphoid Tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"26","key":"10.1016\/j.bbcan.2024.189151_bb0040","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.bbcan.2024.189151_bb0045","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.6004\/jnccn.2020.0057","article-title":"Multiple myeloma, version 3.2021, NCCN clinical practice guidelines in oncology","volume":"18","author":"Kumar","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189151_bb0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11306-005-1102-8","article-title":"Metabolomics: building on a century of biochemistry to guide human health","volume":"1","author":"German","year":"2005","journal-title":"Metabolomics"},{"issue":"3","key":"10.1016\/j.bbcan.2024.189151_bb0055","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/cpt.1538","article-title":"Emerging applications of metabolomics in clinical pharmacology","volume":"106","author":"Pang","year":"2019","journal-title":"Clin.Pharmacol. Ther."},{"key":"10.1016\/j.bbcan.2024.189151_bb0060","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/B978-0-12-818196-6.00002-9","article-title":"Analytical techniques in metabolomics","author":"David","year":"2020","journal-title":"Environmental Metabolomics"},{"issue":"12","key":"10.1016\/j.bbcan.2024.189151_bb0065","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1093\/clinchem\/hvab184","article-title":"Metabolomics in clinical practice: improving diagnosis and informing management","volume":"67","author":"Odom","year":"2021","journal-title":"Clin. Chem."},{"issue":"7","key":"10.1016\/j.bbcan.2024.189151_bb0070","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3390\/metabo11070423","article-title":"Metabolomic laboratory-developed tests: current status and perspectives","volume":"11","author":"Lichtenberg","year":"2021","journal-title":"Metabolites"},{"key":"10.1016\/j.bbcan.2024.189151_bb0075","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.bbcan.2024.189151_bb0080","author":"Haddaway"},{"issue":"16\u201317","key":"10.1016\/j.bbcan.2024.189151_bb0090","first-page":"1316","article-title":"QUADOMICS: an adaptation of the quality assessment of diagnostic accuracy assessment (QUADAS) for the evaluation of the methodological quality of studies on the diagnostic accuracy of \u201c-omics\u201d-based technologies","volume":"41","year":"2008","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.bbcan.2024.189151_bb0095","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2288-3-25","article-title":"The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews","volume":"3","author":"Whiting","year":"2003","journal-title":"BMC Med. Res. Methodol."},{"issue":"W1","key":"10.1016\/j.bbcan.2024.189151_bb0100","doi-asserted-by":"crossref","first-page":"W388","DOI":"10.1093\/nar\/gkab382","article-title":"MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights","volume":"49","author":"Pang","year":"2021","journal-title":"Nucleic Acids Res."},{"issue":"19","key":"10.1016\/j.bbcan.2024.189151_bb0105","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1002\/elps.201200606","article-title":"Differences and similarities between LC-MS derived serum fingerprints of patients with B-cell malignancies","volume":"34","author":"Piszcz","year":"2013","journal-title":"Electrophoresis"},{"issue":"13","key":"10.1016\/j.bbcan.2024.189151_bb0110","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.3390\/molecules24132367","article-title":"The Metabolomic profile of lymphoma subtypes: a pilot study","volume":"24","author":"Barberini","year":"2019","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.bbcan.2024.189151_bb0115","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1038\/s41467-022-31248-w","article-title":"Blocking glycine utilization inhibits multiple myeloma progression by disrupting glutathione balance","volume":"13","author":"Xia","year":"2022","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.bbcan.2024.189151_bb0120","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/bjh.18684","article-title":"Proline promotes proliferation and drug resistance of multiple myeloma by downregulation of proline dehydrogenase","volume":"201","author":"Zhang","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bbcan.2024.189151_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118852","article-title":"Metabolic markers for diagnosis and risk-prediction of multiple myeloma","volume":"265","author":"Fei","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.bbcan.2024.189151_bb0130","article-title":"Serum abnormal metabolites for evaluating therapeutic response and prognosis of patients with multiple myeloma","volume":"12","author":"Wei","year":"2022","journal-title":"Front. Oncol."},{"issue":"11","key":"10.1016\/j.bbcan.2024.189151_bb0135","first-page":"3935","article-title":"Identification of metabolic biomarkers to predict treatment outcome and disease progression in multiple myeloma","volume":"10","author":"Zhao","year":"2020","journal-title":"Am. J. Cancer Res."},{"issue":"17","key":"10.1016\/j.bbcan.2024.189151_bb0140","doi-asserted-by":"crossref","first-page":"4770","DOI":"10.1158\/1078-0432.CCR-12-2917","article-title":"Multiple myeloma patients have a specific serum metabolomic profile that changes after achieving complete remission","volume":"19","author":"Puchades-Carrasco","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"51","key":"10.1016\/j.bbcan.2024.189151_bb0145","doi-asserted-by":"crossref","first-page":"29522","DOI":"10.1039\/C9RA04458B","article-title":"Serum metabolomic alterations in multiple myeloma revealed by targeted and untargeted metabolomics approaches: a pilot study","volume":"9","author":"Chanukuppa","year":"2019","journal-title":"RSC Adv."},{"key":"10.1016\/j.bbcan.2024.189151_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.00884","article-title":"Analysis of the metabolic characteristics of serum samples in patients with multiple myeloma","volume":"9","author":"Du","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.bbcan.2024.189151_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0202045","article-title":"The metabolomic plasma profile of myeloma patients is considerably different from healthy subjects and reveals potential new therapeutic targets","volume":"13","author":"Steiner","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2024.189151_bb0160","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.12918","article-title":"Nontargeted and targeted metabolomics approaches reveal the key amino acid alterations involved in multiple myeloma","volume":"10","author":"Yue","year":"2022","journal-title":"PeerJ"},{"issue":"1","key":"10.1016\/j.bbcan.2024.189151_bb0165","doi-asserted-by":"crossref","first-page":"21836","DOI":"10.1038\/s41598-020-75862-4","article-title":"Biochemical phenotyping of multiple myeloma patients at diagnosis reveals a disorder of mitochondrial complexes I and II and a Hartnup-like disturbance as underlying conditions, also influencing different stages of the disease","volume":"10","author":"da Silva","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189151_bb0170","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s40168-020-00854-5","article-title":"Alterations of gut microbiome accelerate multiple myeloma progression by increasing the relative abundances of nitrogen-recycling bacteria","volume":"8","author":"Jian","year":"2020","journal-title":"Microbiome"},{"issue":"4","key":"10.1016\/j.bbcan.2024.189151_bb0175","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.leukres.2014.12.010","article-title":"Plasma fatty acid profile in multiple myeloma patients","volume":"39","author":"Jurczyszyn","year":"2015","journal-title":"Leuk. Res."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189151_bb0180","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s40164-022-00326-6","article-title":"G6PD promotes cell proliferation and dexamethasone resistance in multiple myeloma via increasing anti-oxidant production and activating Wnt\/\u03b2-catenin pathway","volume":"11","author":"Li","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2024.189151_bb0185","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ab.2010.07.015","article-title":"Differences in metabolite profile between blood plasma and serum","volume":"406","author":"Liu","year":"2010","journal-title":"Anal. Biochem."},{"issue":"3","key":"10.1016\/j.bbcan.2024.189151_bb0190","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11306-007-0082-2","article-title":"Proposed minimum reporting standards for chemical analysis chemical analysis working group (CAWG) metabolomics standards initiative (MSI)","volume":"3","author":"Sumner","year":"2007","journal-title":"Metabolomics"},{"issue":"3","key":"10.1016\/j.bbcan.2024.189151_bb0195","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11306-007-0068-0","article-title":"Minimum reporting standards for plant biology context information in metabolomic studies","volume":"3","author":"Fiehn","year":"2007","journal-title":"Metabolomics"},{"issue":"3","key":"10.1016\/j.bbcan.2024.189151_bb0200","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11306-007-0077-z","article-title":"Standard reporting requirements for biological samples in metabolomics experiments: mammalian\/in vivo experiments","volume":"3","author":"Griffin","year":"2007","journal-title":"Metabolomics"},{"issue":"3","key":"10.1016\/j.bbcan.2024.189151_bb0205","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11306-007-0080-4","article-title":"Standard reporting requirements for biological samples in metabolomics experiments: microbial and in vitro biology experiments","volume":"3","author":"van der Werf","year":"2007","journal-title":"Metabolomics"},{"issue":"3","key":"10.1016\/j.bbcan.2024.189151_bb0210","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s11306-006-0040-4","article-title":"Proposed reporting requirements for the description of NMR-based metabolomics experiments","volume":"3","author":"Rubtsov","year":"2007","journal-title":"Metabolomics"},{"issue":"7","key":"10.1016\/j.bbcan.2024.189151_bb0215","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/s41592-021-01197-1","article-title":"Mass spectrometry-based metabolomics: a guide for annotation, quantification and best reporting practices","volume":"18","author":"Alseekh","year":"2021","journal-title":"Nat. Methods"},{"issue":"1","key":"10.1016\/j.bbcan.2024.189151_bb0220","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11306-017-1299-3","article-title":"Critical review of reporting of the data analysis step in metabolomics","volume":"14","author":"Considine","year":"2017","journal-title":"Metabolomics"},{"issue":"2","key":"10.1016\/j.bbcan.2024.189151_bb0225","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.cmet.2018.09.022","article-title":"Profound perturbation of the metabolome in obesity is associated with health risk","volume":"29","author":"Cirulli","year":"2019","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189151_bb0230","doi-asserted-by":"crossref","first-page":"4571","DOI":"10.1038\/s41598-022-08429-0","article-title":"Effect of serum sample storage temperature on metabolomic and proteomic biomarkers","volume":"12","author":"Valo","year":"2022","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.bbcan.2024.189151_bb0235","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nrm3314","article-title":"Innovation: metabolomics: the apogee of the omics trilogy","volume":"13","author":"Patti","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189151_bb0240","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s12276-020-0375-3","article-title":"Amino acids in cancer","volume":"52","author":"Lieu","year":"2020","journal-title":"Exp. Mol. Med."},{"issue":"3","key":"10.1016\/j.bbcan.2024.189151_bb0245","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","article-title":"The Warburg effect: how does it benefit Cancer cells?","volume":"41","author":"Liberti","year":"2016","journal-title":"Trends Biochem.Sci."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189151_bb0250","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.94543","article-title":"Glutamine-derived 2-hydroxyglutarate is associated with disease progression in plasma cell malignancies","volume":"3","author":"Gonsalves","year":"2018","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.bbcan.2024.189151_bb0255","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-01-690743","article-title":"Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target","volume":"128","author":"Bolzoni","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bbcan.2024.189151_bb0260","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1111\/cas.12529","article-title":"Expression of L-type amino acid transporter 1 (LAT1) as a prognostic and therapeutic indicator in multiple myeloma","volume":"105","author":"Isoda","year":"2014","journal-title":"Cancer Sci."},{"issue":"22","key":"10.1016\/j.bbcan.2024.189151_bb0265","doi-asserted-by":"crossref","first-page":"35863","DOI":"10.18632\/oncotarget.16262","article-title":"Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells","volume":"8","author":"Thompson","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2024.189151_bb0270","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.canlet.2021.02.020","article-title":"Inhibition of the \u029f-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors","volume":"507","author":"Prelowska","year":"2021","journal-title":"Cancer Lett."},{"issue":"Supplement 1","key":"10.1016\/j.bbcan.2024.189151_bb0275","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1182\/blood-2018-99-111337","article-title":"Myeloma-induced alterations of glutamine metabolism impair bone microenvironment niche in multiple myeloma patients","volume":"132","author":"Toscani","year":"2018","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bbcan.2024.189151_bb0280","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.3390\/cancers12113267","article-title":"Myeloma cells deplete bone marrow glutamine and inhibit osteoblast differentiation limiting asparagine availability","volume":"12","author":"Chiu","year":"2020","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.bbcan.2024.189151_bb0285","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00726-013-1493-1","article-title":"Glycine metabolism in animals and humans: implications for nutrition and health","volume":"45","author":"Wang","year":"2013","journal-title":"Amino Acids"},{"issue":"Supplement_1","key":"10.1016\/j.bbcan.2024.189151_bb0290","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-125452","article-title":"High Glycine promotes proliferation and progression though increase of glutathione synthesis in multiple myeloma","volume":"134","author":"Xia","year":"2019","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bbcan.2024.189151_bb0295","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1002\/ijc.34353","article-title":"Target enzymes in serine-glycine-one-carbon metabolic pathway for cancer therapy","volume":"152","author":"Sun","year":"2023","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2024.189151_bb0300","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40170-017-0169-9","article-title":"Bortezomib resistance in multiple myeloma is associated with increased serine synthesis","volume":"5","author":"Zaal","year":"2017","journal-title":"Cancer Metab."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189151_bb0305","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/bjh.16503","article-title":"Phosphoglycerate dehydrogenase promotes proliferation and bortezomib resistance through increasing reduced glutathione synthesis in multiple myeloma","volume":"190","author":"Wu","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189151_bb0310","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40164-020-00196-w","article-title":"Targeting phosphoglycerate dehydrogenase in multiple myeloma","volume":"10","author":"Elsaadi","year":"2021","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.bbcan.2024.189151_bb0315","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3389\/fonc.2020.00776","article-title":"Proline metabolism in tumor growth and metastatic progression","volume":"10","author":"D\u2019Aniello","year":"2020","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.bbcan.2024.189151_bb0320","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0045190","article-title":"Functional specialization in proline biosynthesis of melanoma","volume":"7","author":"De Ingeniis","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bbcan.2024.189151_bb0325","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13046-022-02250-3","article-title":"Pyrroline-5-carboxylate reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis","volume":"41","author":"Oudaert","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2024.189151_bb0330","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.807271","article-title":"Targeting tryptophan catabolism in Cancer immunotherapy era: challenges and perspectives","volume":"13","author":"Peyraud","year":"2022","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.bbcan.2024.189151_bb0335","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ccell.2018.02.005","article-title":"Tumor-repopulating cells induce PD-1 expression in CD8 T cells by transferring kynurenine and AhR activation","volume":"33","author":"Liu","year":"2018","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.bbcan.2024.189151_bb0340","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41375-019-0558-x","article-title":"Targeting tryptophan catabolic kynurenine pathway enhances antitumor immunity and cytotoxicity in multiple myeloma","volume":"34","author":"Ray","year":"2020","journal-title":"Leukemia"},{"issue":"44","key":"10.1016\/j.bbcan.2024.189151_bb0345","doi-asserted-by":"crossref","first-page":"6747","DOI":"10.1038\/s41388-020-01480-z","article-title":"Multifaceted role of branched-chain amino acid metabolism in cancer","volume":"39","author":"Peng","year":"2020","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.bbcan.2024.189151_bb0350","doi-asserted-by":"crossref","first-page":"237","DOI":"10.15430\/JCP.2021.26.4.237","article-title":"Role of branched-chain amino acid metabolism in tumor development and Progression.J","volume":"26","author":"Jung","year":"2021","journal-title":"Cancer Prev."},{"issue":"113390","key":"10.1016\/j.bbcan.2024.189151_bb0355","article-title":"The role of branched chain amino acids metabolic disorders in tumorigenesis and progression","volume":"153","author":"Wang","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"10","key":"10.1016\/j.bbcan.2024.189151_bb0360","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.3390\/ijms20102428","article-title":"The L-type amino acid transporter LAT1-an emerging target in Cancer","volume":"20","author":"H\u00e4fliger","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189151_bb0365","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3390\/metabo11010051","article-title":"L-carnitine and Acylcarnitines: mitochondrial biomarkers for precision medicine","volume":"11","author":"McCann","year":"2021","journal-title":"Metabolites"},{"issue":"5","key":"10.1016\/j.bbcan.2024.189151_bb0370","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1074\/mcp.RA119.001390","article-title":"Metabolic, anti-apoptotic and immune evasion strategies of primary human myeloma cells indicate adaptations to hypoxia","volume":"18","author":"Janker","year":"2019","journal-title":"Mol. Cell. Proteomics"},{"issue":"3","key":"10.1016\/j.bbcan.2024.189151_bb0375","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10173","article-title":"Multiple myeloma and fatty acid metabolism","volume":"3","author":"Masarwi","year":"2019","journal-title":"JBMR Plus."},{"issue":"2","key":"10.1016\/j.bbcan.2024.189151_bb0380","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056422","article-title":"Proton NMR-based metabolite analyses of archived serial paired serum and urine samples from myeloma patients at different stages of disease activity identifies acetylcarnitine as a novel marker of active disease","volume":"8","author":"Lodi","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.bbcan.2024.189151_bb0385","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/bjh.12935","article-title":"Body size and multiple myeloma mortality: a pooled analysis of 20 prospective studies","volume":"166","author":"Teras","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"Supplement 1","key":"10.1016\/j.bbcan.2024.189151_bb0390","first-page":"122","article-title":"New bone cell type identified as driver of drug resistance in multiple myeloma: the bone marrow adipocyte","volume":"130","author":"Falank","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bbcan.2024.189151_bb0395","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227455","article-title":"Concurrent lipidomics and proteomics on malignant plasma cells from multiple myeloma patients: probing the lipid metabolome","volume":"15","author":"Mohamed","year":"2020","journal-title":"PLoSOne"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X24000829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X24000829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T23:12:07Z","timestamp":1737587527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X24000829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":78,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0304419X24000829"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2024.189151","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolomic biomarkers of multiple myeloma: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2024.189151","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"189151"}}